1.74 -0.14 (-7.45%) | 04-24 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.49 | 1-year : | 2.83 |
Resists | First : | 2.13 | Second : | 2.43 |
Pivot price | 1.89 | |||
Supports | First : | 1.65 | Second : | 1.38 |
MAs | MA(5) : | 1.76 | MA(20) : | 1.97 |
MA(100) : | 2.15 | MA(250) : | 2.68 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 26.9 | D(3) : | 21 |
RSI | RSI(14): 40.8 | |||
52-week | High : | 5.69 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VOR ] has closed above bottom band by 26.6%. Bollinger Bands are 9.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 1.86 - 1.87 | 1.87 - 1.88 |
Low: | 1.71 - 1.72 | 1.72 - 1.73 |
Close: | 1.73 - 1.74 | 1.74 - 1.75 |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Tue, 23 Apr 2024
Vor Biopharma (NYSE:VOR) Earns "Outperform" Rating from Wedbush - MarketBeat
Thu, 04 Apr 2024
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock - Yahoo Finance
Tue, 02 Apr 2024
VOR Stock Price and Chart — NASDAQ:VOR — TradingView - TradingView
Mon, 25 Mar 2024
What is the Market's View on Vor Biopharma Inc (VOR) Stock's Price and Volume Trends Monday? - InvestorsObserver
Thu, 21 Mar 2024
Stifel cuts Vor Biopharma stock target to $12, maintains buy rating By Investing.com - Investing.com
Wed, 20 Mar 2024
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 68 (M) |
Shares Float | 32 (M) |
Held by Insiders | 1.2 (%) |
Held by Institutions | 88.5 (%) |
Shares Short | 3,240 (K) |
Shares Short P.Month | 2,980 (K) |
EPS | -1.75 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.22 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -31.7 % |
Return on Equity (ttm) | -58.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.8 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -100 (M) |
Levered Free Cash Flow | -58 (M) |
PE Ratio | -1 |
PEG Ratio | 0 |
Price to Book value | 0.78 |
Price to Sales | 0 |
Price to Cash Flow | -1.19 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |